2025 Germany Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 Germany Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in Amyotrophic Lateral Sclerosis (ALS) treatment in Germany include NeuroSense Therapeutics, Biogen Inc., Sanofi S.A., and BrainStorm Cell Therapeutics. NeuroSense Therapeutics is conducting a Phase IIb clinical trial (PARADIGM trial) in Germany for its drug candidate PrimeC, which targets multiple ALS pathogenic mechanisms and received regulatory approval to enroll German patients. Biogen is notable for its development of tofersen, an investigational therapy targeting genetic causes of ALS, and has received orphan drug designation from the European Medicines Agency (EMA). Sanofi, another major global player, markets Rilutek (riluzole), approved for ALS treatment and is focused on innovation and global collaboration in ALS therapies. BrainStorm, based in New York but active globally including Germany, develops the stem cell-based therapy NurOwn and is advancing its Phase 3 data to build a stronger case for approval after earlier setbacks.
These companies benefit from Germany’s advanced healthcare infrastructure, powerful research initiatives, and supportive regulatory frameworks that foster innovative ALS treatment development. German clinics also integrate multimodal approaches including stem cell therapy, gene therapy, and neuroprotection, with specialized patient monitoring systems to tailor treatments dynamically. The collaborative environment between pharmaceutical firms, research institutions, and specialized ALS centers strengthens Germany’s role as a hub for ALS therapeutic advancements and clinical trials involving leading industry players.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in Amyotrophic Lateral Sclerosis (ALS) treatment in Germany include NeuroSense Therapeutics, Biogen Inc., Sanofi S.A., and BrainStorm Cell Therapeutics. NeuroSense Therapeutics is conducting a Phase IIb clinical trial (PARADIGM trial) in Germany for its drug candidate PrimeC, which targets multiple ALS pathogenic mechanisms and received regulatory approval to enroll German patients. Biogen is notable for its development of tofersen, an investigational therapy targeting genetic causes of ALS, and has received orphan drug designation from the European Medicines Agency (EMA). Sanofi, another major global player, markets Rilutek (riluzole), approved for ALS treatment and is focused on innovation and global collaboration in ALS therapies. BrainStorm, based in New York but active globally including Germany, develops the stem cell-based therapy NurOwn and is advancing its Phase 3 data to build a stronger case for approval after earlier setbacks.
These companies benefit from Germany’s advanced healthcare infrastructure, powerful research initiatives, and supportive regulatory frameworks that foster innovative ALS treatment development. German clinics also integrate multimodal approaches including stem cell therapy, gene therapy, and neuroprotection, with specialized patient monitoring systems to tailor treatments dynamically. The collaborative environment between pharmaceutical firms, research institutions, and specialized ALS centers strengthens Germany’s role as a hub for ALS therapeutic advancements and clinical trials involving leading industry players.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
